Amicus Therapeutics Revenue and Competitors

Claim your profile

Cranbury, NJ USA

Location

$843.1M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Amicus Therapeutics's estimated annual revenue is currently $91.2M per year.(i)
  • Amicus Therapeutics received $300.0M in venture funding in February 2018.
  • Amicus Therapeutics's estimated revenue per employee is $134,580
  • Amicus Therapeutics's total funding is $843.1M.

Employee Data

  • Amicus Therapeutics has 678 Employees.(i)
  • Amicus Therapeutics grew their employee count by 1% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.9M70-3%N/AN/A
#2
$12.7M8215%N/AN/A
#3
$100.9M46517%N/AN/A
#4
$14.7M10418%$206.4MN/A
#5
$492.2M175212%$568MN/A
#6
$1.7M2729%N/AN/A
#7
$5M78-8%N/AN/A
#8
$3.5M35-8%$33.5MN/A
#9
$2M1318%N/AN/A
#10
$40.5M2615%N/AN/A

Amicus Therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. We have a unique set of platform technologies and medicines in development for patients living with the Lysosomal Storage Disorders Fabry disease and Pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. The needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. Our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. Several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. Our Amicus footprint spans 27 countries including our global headquarters in Cranbury, NJ and international headquarters in Gerrards Cross UK. Additional international office locations include Canada, Germany, Italy, The Netherlands, Spain, France, and Japan. More information about Amicus and our career opportunities can be found at www.amicusrx.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$843.1M

Total Funding

678

Number of Employees

$91.2M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Amicus Therapeutics News

2022-04-20 - Insider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD ...

Insider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells 2,214 Shares of Stock. Posted by admin on Apr 20th, 2022.

2022-04-17 - Amicus Therapeutics, Inc. (NASDAQ:FOLD) Expected to ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Expected to Announce Quarterly Sales of $79.69 Million. Posted by admin on Apr 15th, 2022.

2022-04-17 - Amicus Announces Issuance of New US Composition of ...

PHILADELPHIA, April 19, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company...

2021-11-09 - Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates - Form 8-K

Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates 3Q21 Total Galafold® Revenue of $79.5M - an 18% increase over 3Q20 Reiterating 2021 Revenue Guidance of $300M-$315M AT-GAA BLA and NDA for Pompe Disease Accepted for Review by the U.S. FDA; Marketing Aut ...

2021-08-02 - Amicus Therapeutics : Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease

PHILADELPHIA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Commission has approved Galafold® (migalastat) fo ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$750M7802%$1.3B
#2
$190M9733%N/A
#3
$750M103922%N/A
#4
$262.8M134132%N/A
#5
$506.3M258361%N/A

Amicus Therapeutics Funding

DateAmountRoundLead InvestorsReference
2003-10-01$1.0MPrivate OfferingArticle
2004-05-13$31.0MBCanaan PartnersArticle
2005-09-09$55.0MCQuaker BioVenturesArticle
2006-05-19$86.2MUndisclosedMorgan Stanley, Goldman Sachs and CoArticle
2006-09-15$60.0MDNew Enterprise AssociatesArticle
2006-09-28$60.0MUndisclosedArticle
2007-04-03$86.2MUndisclosedArticle
2007-06-04$60.0MUndisclosedMorgan Stanley and Co Incorpor, Merrill Lynch and CoArticle
2010-02-26$18.5MUndisclosedLeerink Swann LLCArticle
2012-03-05$54.0MUndisclosedLeerink Swann LLC , Cowen and Company LLCArticle
2013-12-05$15.0MUndisclosedArticle
2014-01-02$25.0MUndisclosedMidCap Financial, LLCArticle
2014-11-21$90.0MUndisclosedMultipleArticle
2014-11-25$103.5MUndisclosedJ.P. Morgan Securities LLCArticle
2015-06-15$258.8MUndisclosedJ.P. Morgan Securities LLCArticle
2017-07-14$258.8MUndisclosedJ.P. Morgan Securities LLCArticle
2018-02-19$300.0MUndisclosedBofA Merrill LynchArticle